Responses
Featured Posters: Poster Rounds with the Professors
AS11. Ovarian cancer
PR073/#425 Senaparib, a PARP inhibitor, in patients with BRCA1/2 mutated platinum sensitive recurrent ovarian cancer: subgroup analysis from Sabrina study
Compose a Response to This Article
Other responses
No responses have been published for this article.